Molly Gallogly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Molly Gallogly has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- AB Skytte
Cryos International, Aarhus, Denmark
1 shared publication Alexander E. Perl
University of Pennsylvania, Division of Hematology Oncology, Perelman Center for Advanced Medicine, Philadelphia, PA, USA
1 shared publication- Amos Toren
Pediatric Hemato-Oncology, Sheba Medical Center, Ramat Gan, Israel
1 shared publication - Anyull Bohorquez
Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
1 shared publication - Brenda W. Cooper
University Hospitals, Cleveland Medical Center, Cleveland, OH
1 shared publication - Bryan Daly
Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
1 shared publication
Latest Publications
- 23 October 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (11) , 1-8
Stem cell transplant and graft versus host disease: designing and implementing a steroid-induced hyperglycemia tool kit
Purpose Patients receiving glucocorticoids for acute graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplant (HSCT) are at risk for developing hyperglycemia and subsequent complications. The primary purpose of this project was to reduce time to medical intervention for steroid-induced hyperglycemia through the implementation of a tailored tool kit for HSCT clinicians. Methods An interdisciplinary team conducted a four-phase project: (1) a baseline chart audit and survey of advanced practice providers (APPs), (2) development of a tool kit and educational materials, (3) education of the HSCT team, and (4) post tool kit implementation chart audit and APP surveys. Results Patients at baseline (N = 15) and post tool kit implementation (N = 8) were diagnosed with acute GVHD with ≥ 0.5 mg/kg/day prednisone and subsequent steroid-induced hyperglycemia. The average number of days to medical intervention was 46 at baseline, reduced to 10 days at 3 months and 9 days at 6 months post tool kit implementation. Metrics used to evaluate changes in APP practice noted an increase in hemoglobin A1c and glucose monitoring from baseline to post tool kit implementation. There was no change in APP confidence scores pre and post tool kit (N = 29). Conclusion The tool kit designed in this study is an evidence-based resource created by an interdisciplinary team that led to earlier intervention to improve glycemic control in HSCT patients. Due to the complex nature of HSCT patients, a proactive and stepwise approach to managing hyperglycemia is critical to monitoring patients at risk and initiating treatment early to mitigate symptoms.
- 23 October 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (11) , 1-8
Stem cell transplant and graft versus host disease: designing and implementing a steroid-induced hyperglycemia tool kit
Purpose Patients receiving glucocorticoids for acute graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplant (HSCT) are at risk for developing hyperglycemia and subsequent complications. The primary purpose of this project was to reduce time to medical intervention for steroid-induced hyperglycemia through the implementation of a tailored tool kit for HSCT clinicians. Methods An interdisciplinary team conducted a four-phase project: (1) a baseline chart audit and survey of advanced practice providers (APPs), (2) development of a tool kit and educational materials, (3) education of the HSCT team, and (4) post tool kit implementation chart audit and APP surveys. Results Patients at baseline (N = 15) and post tool kit implementation (N = 8) were diagnosed with acute GVHD with ≥ 0.5 mg/kg/day prednisone and subsequent steroid-induced hyperglycemia. The average number of days to medical intervention was 46 at baseline, reduced to 10 days at 3 months and 9 days at 6 months post tool kit implementation. Metrics used to evaluate changes in APP practice noted an increase in hemoglobin A1c and glucose monitoring from baseline to post tool kit implementation. There was no change in APP confidence scores pre and post tool kit (N = 29). Conclusion The tool kit designed in this study is an evidence-based resource created by an interdisciplinary team that led to earlier intervention to improve glycemic control in HSCT patients. Due to the complex nature of HSCT patients, a proactive and stepwise approach to managing hyperglycemia is critical to monitoring patients at risk and initiating treatment early to mitigate symptoms.
- Open Access
- 6 May 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (12)
Chemotherapy and the somatic mutation burden of sperm
Many chemotherapeutic agents impair cancer growth by inducing DNA damage. The impact of these agents on mutagenesis in normal cells, including sperm, is largely unknown. Here, we applied high-fidelity duplex sequencing to 94 samples from 36 individuals exposed to diverse chemotherapies and 32 controls. We found that in many of the sperm samples from men exposed to chemotherapy, the mutation burden was elevated as compared with controls and the expected burden based on trio studies, with 1 patient having a more than 10-fold increase over that expected for age. Saliva from this same individual also had a markedly higher mutation burden. We then validated this finding using other tissues, also finding an increased mutation burden in the blood and liver of many patients exposed to chemotherapy as compared with unexposed controls. Similarly, mice treated with 3 cycles of cisplatin had an increased mutation burden in sperm but also in the liver and hematopoietic progenitor cells. These results suggest an association between cancer therapies and mutation burden, with implications for counseling patients with cancer considering banking sperm before therapy and for cancer survivors considering the trade-offs of using banked sperm as compared with conceiving naturally.
- 6 May 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (12)
Open AccessChemotherapy and the somatic mutation burden of sperm
Many chemotherapeutic agents impair cancer growth by inducing DNA damage. The impact of these agents on mutagenesis in normal cells, including sperm, is largely unknown. Here, we applied high-fidelity duplex sequencing to 94 samples from 36 individuals exposed to diverse chemotherapies and 32 controls. We found that in many of the sperm samples from men exposed to chemotherapy, the mutation burden was elevated as compared with controls and the expected burden based on trio studies, with 1 patient having a more than 10-fold increase over that expected for age. Saliva from this same individual also had a markedly higher mutation burden. We then validated this finding using other tissues, also finding an increased mutation burden in the blood and liver of many patients exposed to chemotherapy as compared with unexposed controls. Similarly, mice treated with 3 cycles of cisplatin had an increased mutation burden in sperm but also in the liver and hematopoietic progenitor cells. These results suggest an association between cancer therapies and mutation burden, with implications for counseling patients with cancer considering banking sperm before therapy and for cancer survivors considering the trade-offs of using banked sperm as compared with conceiving naturally.
- 2 November 2017
- Published by Taylor & Francis in Expert Review of Precision Medicine and Drug Development
- Vol. 2 (6) , 307-320
Midostaurin and emerging FLT3 inhibitors for the treatment of adults with newly diagnosed acute myeloid leukemia with the FLT3 mutation
Introduction: FLT3 internal tandem duplication mutations are independent risk factors for worse overall survival (OS) and increased relapse risk in AML patients and thus are an attractive target for pharmacotherapy. Midostaurin is the first FLT3 inhibitor approved for the treatment of FLT3-mutant AML. Other tyrosine kinase inhibitors with varying specificity for FLT3 mutations are in development. Areas covered: The authors provide an overview of FLT3 inhibitors, then describe the characterization, clinical efficacy, toxicities, and approval of midostaurin therapy for AML. Discussion was synthesized from primary and review manuscripts addressing FLT3-mutant AML utilizing midostaurin and other FLT3 inhibitors; such were identified by searching the PubMed database for ‘midsotaurin,’ ‘FLT3 inhibitor,’ and ‘FLT3 AML.’ Ongoing clinical trials were identified by searching ClinicalTrials.gov for ‘midostaurin’ and ‘FLT3.’ Expert commentary: The addition of midostaurin to standard induction and consolidation chemotherapy in young, fit patients who have newly diagnosed FLT3-mut AML improved OS, event-free survival, and disease-free survival, leading to its international approval. The benefit of adding midostaurin to less intensive therapies in elderly or frail patients is less clear, and has not been evaluated in a randomized trial. The role of midostaurin maintenance therapy after allogeneic hematopoietic cell transplant is an area of active investigation.
- 2 November 2017
- Published by Taylor & Francis in Expert Review of Precision Medicine and Drug Development
- Vol. 2 (6) , 307-320
Midostaurin and emerging FLT3 inhibitors for the treatment of adults with newly diagnosed acute myeloid leukemia with the FLT3 mutation
Introduction: FLT3 internal tandem duplication mutations are independent risk factors for worse overall survival (OS) and increased relapse risk in AML patients and thus are an attractive target for pharmacotherapy. Midostaurin is the first FLT3 inhibitor approved for the treatment of FLT3-mutant AML. Other tyrosine kinase inhibitors with varying specificity for FLT3 mutations are in development. Areas covered: The authors provide an overview of FLT3 inhibitors, then describe the characterization, clinical efficacy, toxicities, and approval of midostaurin therapy for AML. Discussion was synthesized from primary and review manuscripts addressing FLT3-mutant AML utilizing midostaurin and other FLT3 inhibitors; such were identified by searching the PubMed database for ‘midsotaurin,’ ‘FLT3 inhibitor,’ and ‘FLT3 AML.’ Ongoing clinical trials were identified by searching ClinicalTrials.gov for ‘midostaurin’ and ‘FLT3.’ Expert commentary: The addition of midostaurin to standard induction and consolidation chemotherapy in young, fit patients who have newly diagnosed FLT3-mut AML improved OS, event-free survival, and disease-free survival, leading to its international approval. The benefit of adding midostaurin to less intensive therapies in elderly or frail patients is less clear, and has not been evaluated in a randomized trial. The role of midostaurin maintenance therapy after allogeneic hematopoietic cell transplant is an area of active investigation.